In this article, we will look at the 14 Best Long Term Low Volatility Stocks to Buy Right Now.
Mike Wilson, Morgan Stanley CIO and chief U.S. equity strategist, appeared on CNBC’s ‘Squawk Box’ to discuss several aspects of the stock market, including the latest market trends and the state of the economy.
He stated that his differentiated view is that we have been in a rolling recession for the past 2-3 years, with a weak private economy. Now, however, we are in a rolling recovery, as according to Wilson the recession ended with the DOGE layoffs. Looking at the data closely, and as documented by the firm, there was a spike in layoffs and a low in jobs creations, which is being proved by the revisions now.
READ ALSO: 11 Best Small Cap Stocks with the Highest Upside and 9 Best Healthcare Stocks with the Highest Upside.
Wilson further stated that the stock market is smarter than all of us, which is why it figured this trend out. The confirmation for us, according to him, is that the earnings revisions have exploded higher in a way they only do in a new economic cycle.
With these trends in view, let’s look at the best long-term low volatility stocks to buy right now.
Our Methodology
We used Finviz to compile a list of top stocks with a 5-year revenue growth above 10% and beta below 1. We then selected the top 14 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on October 20.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
14 Best Long Term Low Volatility Stocks to Buy Right Now
14. Novo Nordisk A/S (NYSE:NVO)
5-Year Revenue Growth: 19.77%
Beta: 0.33
Number of Hedge Fund Holders: 45
Novo Nordisk A/S (NYSE:NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) in a report released on October 17, setting a price target of DKK500.
The rating followed Novo Nordisk’s (NYSE:NVO) announcement on October 15 that it entered into a definitive asset purchase and license agreement with Omeros Corporation for the candidate drug zaltenibart, previously known as OMS906, in clinical development for rare blood and kidney disorders.
Management reported that the terms of the agreement provide Novo Nordisk A/S (NYSE:NVO) exclusive global rights for the development and commercialization of the drug in all indications. Omeros Corporation is eligible to receive upfront and near-term milestone payments worth $340 million, up to a “total of $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales”.
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
13. AstraZeneca PLC (NASDAQ:AZN)
5-Year Revenue Growth: 17.07%
Beta: 0.17
Number of Hedge Fund Holders: 48
AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to buy right now. AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P. Morgan analyst Richard Vosser on October 20, who assigned the stock a Buy rating with a £140 price target.
The rating update followed AstraZeneca PLC’s (NASDAQ:AZN) announcement of positive results from the TROPION-Breast02 Phase III trial on October 19. The results showed that AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) exhibited a clinically meaningful and statistically significant improvement for “the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.”
Management reported that Datroway is the first and only therapy to considerably improve the overall survival compared to chemotherapy in this patient population, showing a “highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death”.
AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.
Hedge Fund Resource Center